1. Home
  2. TACT vs LGVN Comparison

TACT vs LGVN Comparison

Compare TACT & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TransAct Technologies Incorporated

TACT

TransAct Technologies Incorporated

HOLD

Current Price

$3.93

Market Cap

35.7M

Sector

Technology

ML Signal

HOLD

Logo Longeveron Inc.

LGVN

Longeveron Inc.

HOLD

Current Price

$0.81

Market Cap

34.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TACT
LGVN
Founded
1996
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Computer peripheral equipment
Medicinal Chemicals and Botanical Products
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
35.7M
34.0M
IPO Year
1996
2021

Fundamental Metrics

Financial Performance
Metric
TACT
LGVN
Price
$3.93
$0.81
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$5.00
$3.00
AVG Volume (30 Days)
57.9K
367.9K
Earning Date
05-08-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
87.88
50.76
EPS
0.07
N/A
Revenue
N/A
$709,000.00
Revenue This Year
$10.36
N/A
Revenue Next Year
N/A
$10.81
P/E Ratio
$55.57
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.06
$0.48
52 Week High
$5.70
$1.80

Technical Indicators

Market Signals
Indicator
TACT
LGVN
Relative Strength Index (RSI) 63.56 47.89
Support Level $3.67 $0.74
Resistance Level $4.76 $0.86
Average True Range (ATR) 0.20 0.06
MACD 0.05 -0.00
Stochastic Oscillator 80.51 62.76

Price Performance

Historical Comparison
TACT
LGVN

About TACT TransAct Technologies Incorporated

Transact Technologies Inc develops and sells software-driven technology and printing solutions. The company's software is sold under BOHA, AccuDate, Epic, EPICENTRAL, Ithaca, and Printrex brand names. It also provides supplies and consumables used in the printing and scanning activities to restaurant and hospitality, banking, retail, casino and gaming, point of sale automation, lottery, medical, mobile, oil, and gas markets. Majority of the revenue is derived from the casinos and gaming industry followed by the Foodservice technology market. Its geographical segments are the United States and International, of which the majority of its revenue comes from the United States.

About LGVN Longeveron Inc.

Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.

Share on Social Networks: